Advances for its 2 lead programs, the Neo-Urinary Conduit™ and Neo-Kidney Augment™ Read more…
The private placement of $15 M aggregate principal amount of Senior Secured Convertible Notes Read more…
Definitive agreements for a 1 month bridge loan with leading investors Read more…
TNGN common stock will begin trading on the OTCQB Read more…
Adjusted net loss of $4.5M, or $1.89 per share Read more…
Common stock will begin trading on a split-adjusted basis on 6/14/12 Read more…
180 days to fix the share price Read more…
Report Card … so far Read more…
Adjusted net loss of $4.4M, or $0.18 per share Read more…
TNGN will seek stockholder approval of Reverse Stock Split at May Annual Meeting Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.